Cambium Bio Limited (ASX:CMB)

The quarterly report for Cambium Bio Limited details significant advancements in their clinical and regulatory efforts for Elate Ocular®, a treatment for dry eye disease. During the quarter, the company secured a strategic investment of A$2.4 million through a placement with its major shareholder, ZYBT, enhancing its financial position. The report highlights a successful Type D meeting with the FDA, confirming a single pivotal trial pathway, which will expedite the Biologics License Application (BLA) process. Cambium Bio also continued progress in the Chemistry, Manufacturing, and Controls (CMC) program to prepare for Phase 3 clinical trials. Financially, the company reported a net operating cash outflow of A$0.792 million, with a closing cash balance of A$2.246 million. The company is pursuing multiple funding strategies to support the Phase 3 program and aims to achieve key milestones, including starting the pivotal Phase 3 trial in H2 CY 2026 and submitting a rolling BLA by mid-CY 2028.